However, consistent with data in Western patients [14], high MYC/BCL2 co‐expression, which has been observed in 18·4% of patients in China, has been associated with inferior survival in R‐CHOP‐treated Chinese patients with DLBCL [15, 16]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.